Featured
-
-
-
Review Article |
Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings. Epigenetic and other molecularly-based diagnostic strategies have emerged to complement traditional diagnostic procedures, thereby improving the clinical management of patients with CUP. Herein, the authors present the latest data on strategies using epigenetics and other molecular biomarkers to guide therapeutic decisions involving patients with CUP, addressing a previously unmet need.
- Sebastián Moran
- , Anna Martinez-Cardús
- & Manel Esteller
-
News & Views |
Improved diagnosis, therapy and outcomes for patients with CUP
Molecular cancer-classifier assays enable the diagnosis of a single cancer type for most patients with cancer of unknown primary (CUP), thus opening the door to the administration of site-specific therapies. Herein, I discuss how such therapies can improve the survival of patients with CUP, and the resulting paradigm shift towards tissue-of-origin diagnostics and treatments that is now becoming the standard of care for this patient population.
- F. Anthony Greco
-
-
-
Review Article |
Carcinomas of an unknown primary origin—diagnosis and treatment
Carcinomas of an unknown primary origin (CUP) are histologically confirmed metastases for which a primary tumor could not be found despite an extensive diagnostic workup of the patient. The authors of this Review discuss the clinical evaluation of patients with CUP, describe how to identify specific CUP subsets, and outline treatment strategies and outcomes of patients with CUP.
- Christophe Massard
- , Yohann Loriot
- & Karim Fizazi